Agency Information Collection Activities: Proposed Collection; Comment Request, 17614-17615 [2021-06887]
Download as PDF
<![CDATA[
17614
Federal Register / Vol. 86, No. 63 / Monday, April 5, 2021 / Notices
jbell on DSKJLSW7X2PROD with NOTICES
(3) Two oral public comment
sessions: One session will be open to
any newborn screening related topic.
The other public comment period will
specifically address the Committee’s
review of the evidence review process
(e.g., nomination form, consumerfriendly guidance materials, review of
conditions on the RUSP). Please note, if
you wish to register to submit oral
public comments on the review of the
Committee’s evidence review process
we request that you also submit a
written version of your remarks;
(4) Committee discussion of
Continuity of Operations Planning and
COVID–19; and,
(5) Newborn screening data sources.
The agenda for this meeting does not
include any plans for recommending a
condition for inclusion in the RUSP.
However, as noted in the agenda items,
the Committee may hold a vote on
whether or not to recommend a
nominated condition (MPS II) to full
evidence review, which may lead to
such a recommendation at a future time.
Agenda items are subject to change as
priorities dictate. Information about the
ACHDNC, including a roster of members
and past meeting summaries, is also
available on the ACHDNC website
previously listed.
As noted above, members of the
public will have the opportunity to
provide comments. Public participants
providing general oral comments may
submit written statements in advance of
the scheduled meeting. We specifically
request that public participants
providing oral comment on the review
of the Committee’s evidence review
process also submit a written version of
their remarks. Oral comments will be
honored in the order they are requested
and may be limited as time allows.
Requests to provide a written statement
or make oral comments to the ACHDNC
must be submitted via the registration
website by 10:00 a.m. ET on Monday,
May 10, 2021.
Individuals who need special
assistance or another reasonable
accommodation should notify Alaina
Harris at the address and phone number
listed above at least 10 business days
prior to the meeting.
Maria G. Button,
Director, Executive Secretariat.
[FR Doc. 2021–06940 Filed 4–2–21; 8:45 am]
BILLING CODE 4165–15–P
VerDate Sep<11>2014
17:23 Apr 02, 2021
Jkt 253001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The purpose of this
meeting is to evaluate requests for
preclinical development resources for
potential new therapeutics for the
treatment of cancer. The outcome of the
evaluation will provide information to
internal NCI committees that will
decide whether NCI should support
requests and make available contract
resources for development of the
potential therapeutic to improve the
treatment of various forms of cancer.
The research proposals and the
discussions could disclose confidential
trade secrets or commercial property
such as patentable material, and
personal information concerning
individuals associated with the
proposed research projects, the
disclosure of which would constitute a
clearly unwarranted invasion of
personal privacy.
Name of Committee: National Cancer
Institute Special Emphasis Panel; FEB2021
Cycle 37 NExT SEP Committee Meeting.
Date: April 21, 2021.
Time: 9:00 a.m. to 3:00 p.m.
Agenda: To evaluate the NCI Experimental
Therapeutics Program Portfolio.
Place: National Institutes of Health, 9000
Rockville Pike, Building 31, Room 3A44,
Bethesda, Maryland 20892 (WebEx Meeting).
Contact Persons: Barbara Mroczkowski,
Ph.D. Executive Secretary, Discovery
Experimental Therapeutics Program,
National Cancer Institute, NIH, 31 Center
Drive, Room 3A44, Bethesda, MD 20817,
(301) 496–4291, mroczkoskib@mail.nih.gov.
Toby Hecht, Ph.D., Executive Secretary,
Development Experimental Therapeutics
Program, National Cancer Institute, NIH,
9609 Medical Center Drive, Room 3W110,
Rockville, MD 20850, (240) 276–5683,
toby.hecht2@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
PO 00000
Frm 00029
Fmt 4703
Sfmt 4703
Dated: March 30, 2021.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–06890 Filed 4–2–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Agency Information Collection
Activities: Proposed Collection;
Comment Request
In compliance with section
3506(c)(2)(A) of the Paperwork
Reduction Act of 1995 concerning
opportunity for public comment on
proposed collections of information, the
Substance Abuse and Mental Health
Services Administration (SAMHSA)
will publish periodic summaries of
proposed projects. To request more
information on the proposed projects or
to obtain a copy of the information
collection plans, call the SAMHSA
Reports Clearance Officer on (240) 276–
0361.
Comments are invited on: (a) Whether
the proposed collections of information
are necessary for the proper
performance of the functions of the
agency, including whether the
information shall have practical utility;
(b) the accuracy of the agency’s estimate
of the burden of the proposed collection
of information; (c) ways to enhance the
quality, utility, and clarity of the
information to be collected; and (d)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques or
other forms of information technology.
Proposed Project: 2022 National Survey
on Drug Use and Health (OMB No.
0930–0110)
The National Survey on Drug Use and
Health (NSDUH) is a survey of the U.S.
civilian, non-institutionalized
population aged 12 years old or older.
The data are used to determine the
prevalence of use of tobacco products,
alcohol, illicit substances, and illicit use
of prescription drugs. The results are
used by SAMHSA, the Office of
National Drug Control Policy (ONDCP),
federal government agencies, and other
organizations and researchers to
establish policy, direct program
activities, and better allocate resources.
As certain parts of the United States
reduce COVID–19 restrictions, NSDUH
in-person data collection will proceed
where possible. However, to ensure
E:\FR\FM\05APN1.SGM
05APN1
17615
Federal Register / Vol. 86, No. 63 / Monday, April 5, 2021 / Notices
sufficient data are collected to produce
nationally representative estimates for
the 2022 survey, NSDUH will continue
to employ a mix of in-person and webbased modes of administration to allow
those respondents living in areas with
COVID–19 restrictions the opportunity
to participate. If the COVID–19
pandemic subsides to such levels to
allow in-person data collection to
resume nationwide, SAMHSA may
reassess that multimode data collection
model as part of the 2022 NSDUH.
In those areas where in-person data
collection is permitted, NSDUH
protocols, processes, and materials will
continue to reflect the need to ensure
the safety of respondents and field
interviewers with respect to COVID–
19—after initial implementation of such
measures beginning in October 2020—
which include equipping field
interviewers with masks, gloves,
disinfecting wipes, and hand sanitizer
for use during data collection and
providing a COVID–19 risk information
form to all respondents.
In addition, the NSDUH questionnaire
must be updated periodically to reflect
changing substance use and mental
health issues and to continue producing
current data. For the 2022 NSDUH, the
following questionnaire updates are
planned: (1) Replacing the tobacco
module with a redesigned nicotine
module that includes questions about
vaping, removes low priority items to
reduce respondent burden and
eliminates outdated terminology; (2)
revising the marijuana module to
include questions about the use of CBD,
update questions on the mode of
administration and eliminate outdated
terminology and includes changes to the
market information for marijuana
questions; (3) redesigning the adult and
youth mental health services utilization
modules into one Mental Health Service
Utilization model to remove questions
with outdated terminology and include
questions about newer treatments with
recent increases in popularity; and (4)
replacing the drug treatment module
with a redesigned alcohol and drug
treatment module that includes
questions about newer treatments and
those that have increased in popularity,
as well as eliminating outdated
terminology and reducing respondent
burden.
As with all NSDUH/NHSDA 1 surveys
conducted since 1999, the sample size
of the NSDUH main study for 2022 will
be sufficient to permit prevalence
estimates for each of the fifty states and
the District of Columbia. The total
annual burden estimate for the NSDUH
main study is shown below in Table 1.
TABLE 1—ANNUALIZED ESTIMATED BURDEN FOR 2022 NSDUH
Number of
respondents
Instrument
Total
number of
responses
Hours
per
response
Total
burden
hours
Household Screening ...........................................................
Interview ...............................................................................
Screening Verification ..........................................................
Interview Verification ............................................................
168,674
67,507
5,060
10,126
1
1
1
1
168,674
67,507
5,060
10,126
0.083
1.000
0.067
0.067
14,000
67,507
339
678
Total ..............................................................................
168,674
........................
251,367
........................
82,524
Send comments to Carlos Graham,
SAMHSA Reports Clearance Officer,
5600 Fisher Lane, Room 15E57A,
Rockville, MD 20852 OR email him a
copy at carlos.graham@samhsa.hhs.gov.
Written comments should be received
by June 4, 2021.
Carlos Graham,
Social Science Analyst.
[FR Doc. 2021–06887 Filed 4–2–21; 8:45 am]
BILLING CODE 4162–20–P
DEPARTMENT OF HOMELAND
SECURITY
The Coast Guard published a
document in the Federal Register on
March 30, 2021, concerning a notice of
a decision on a consolidation of Coast
Guard boat stations. The document
contained an incorrect docket number.
DATES: This correction is effective April
5, 2021.
FOR FURTHER INFORMATION CONTACT: For
information about this document call or
email Todd Aikins, Coast Guard Office
of Boat Forces; telephone 202–372–
2463, email todd.r.aikins@uscg.mil.
SUPPLEMENTARY INFORMATION:
SUMMARY:
Correction
In the Federal Register of March 30,
2021, in FR Doc. 2021–06461, on page
16604, in the second column, in the
heading, the docket number, ‘‘USCG–
2021–0178’’, is corrected to read
‘‘USCG–2020–0042’’. This corrects the
error in the docket number and will
ensure that this decision notice will be
placed in the same docket as the notice
soliciting comments regarding these
boat stations (85 FR 8601, February 14,
2020).
Coast Guard
[Docket No. USCG–2020–0042]
Consolidation of Redundant Coast
Guard Boat Stations—Decision;
Correction
jbell on DSKJLSW7X2PROD with NOTICES
Responses
per
respondent
Coast Guard, DHS.
Notice; correction to docket
number.
AGENCY:
ACTION:
Dated: March 30, 2021.
J.E. McLeod,
Acting Office Chief, Office of Regulations and
Administrative Law.
[FR Doc. 2021–06876 Filed 4–2–21; 8:45 am]
BILLING CODE 9110–04–P
DEPARTMENT OF HOMELAND
SECURITY
Federal Emergency Management
Agency
[Docket ID: FEMA–2020–0039; OMB No.
1660–0006]
Agency Information Collection
Activities: Submission for OMB
Review; Comment Request; National
Flood Insurance Program Policy Forms
Federal Emergency
Management Agency, Department of
Homeland Security.
ACTION: 30 Day Notice of Reinstatement
and request for comments.
AGENCY:
The Federal Emergency
Management Agency (FEMA), as part of
SUMMARY:
1 Prior to 2002, the NSDUH was referred to as the
National Household Survey on Drug Abuse
(NHSDA).
VerDate Sep<11>2014
17:23 Apr 02, 2021
Jkt 253001
PO 00000
Frm 00030
Fmt 4703
Sfmt 4703
E:\FR\FM\05APN1.SGM
05APN1
]]>Agencies
[Federal Register Volume 86, Number 63 (Monday, April 5, 2021)]
[Notices]
[Pages 17614-17615]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-06887]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Substance Abuse and Mental Health Services Administration
Agency Information Collection Activities: Proposed Collection;
Comment Request
In compliance with section 3506(c)(2)(A) of the Paperwork Reduction
Act of 1995 concerning opportunity for public comment on proposed
collections of information, the Substance Abuse and Mental Health
Services Administration (SAMHSA) will publish periodic summaries of
proposed projects. To request more information on the proposed projects
or to obtain a copy of the information collection plans, call the
SAMHSA Reports Clearance Officer on (240) 276-0361.
Comments are invited on: (a) Whether the proposed collections of
information are necessary for the proper performance of the functions
of the agency, including whether the information shall have practical
utility; (b) the accuracy of the agency's estimate of the burden of the
proposed collection of information; (c) ways to enhance the quality,
utility, and clarity of the information to be collected; and (d) ways
to minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques or other
forms of information technology.
Proposed Project: 2022 National Survey on Drug Use and Health (OMB No.
0930-0110)
The National Survey on Drug Use and Health (NSDUH) is a survey of
the U.S. civilian, non-institutionalized population aged 12 years old
or older. The data are used to determine the prevalence of use of
tobacco products, alcohol, illicit substances, and illicit use of
prescription drugs. The results are used by SAMHSA, the Office of
National Drug Control Policy (ONDCP), federal government agencies, and
other organizations and researchers to establish policy, direct program
activities, and better allocate resources.
As certain parts of the United States reduce COVID-19 restrictions,
NSDUH in-person data collection will proceed where possible. However,
to ensure
[[Page 17615]]
sufficient data are collected to produce nationally representative
estimates for the 2022 survey, NSDUH will continue to employ a mix of
in-person and web-based modes of administration to allow those
respondents living in areas with COVID-19 restrictions the opportunity
to participate. If the COVID-19 pandemic subsides to such levels to
allow in-person data collection to resume nationwide, SAMHSA may
reassess that multimode data collection model as part of the 2022
NSDUH.
In those areas where in-person data collection is permitted, NSDUH
protocols, processes, and materials will continue to reflect the need
to ensure the safety of respondents and field interviewers with respect
to COVID-19--after initial implementation of such measures beginning in
October 2020--which include equipping field interviewers with masks,
gloves, disinfecting wipes, and hand sanitizer for use during data
collection and providing a COVID-19 risk information form to all
respondents.
In addition, the NSDUH questionnaire must be updated periodically
to reflect changing substance use and mental health issues and to
continue producing current data. For the 2022 NSDUH, the following
questionnaire updates are planned: (1) Replacing the tobacco module
with a redesigned nicotine module that includes questions about vaping,
removes low priority items to reduce respondent burden and eliminates
outdated terminology; (2) revising the marijuana module to include
questions about the use of CBD, update questions on the mode of
administration and eliminate outdated terminology and includes changes
to the market information for marijuana questions; (3) redesigning the
adult and youth mental health services utilization modules into one
Mental Health Service Utilization model to remove questions with
outdated terminology and include questions about newer treatments with
recent increases in popularity; and (4) replacing the drug treatment
module with a redesigned alcohol and drug treatment module that
includes questions about newer treatments and those that have increased
in popularity, as well as eliminating outdated terminology and reducing
respondent burden.
As with all NSDUH/NHSDA \1\ surveys conducted since 1999, the
sample size of the NSDUH main study for 2022 will be sufficient to
permit prevalence estimates for each of the fifty states and the
District of Columbia. The total annual burden estimate for the NSDUH
main study is shown below in Table 1.
---------------------------------------------------------------------------
\1\ Prior to 2002, the NSDUH was referred to as the National
Household Survey on Drug Abuse (NHSDA).
Table 1--Annualized Estimated Burden for 2022 NSDUH
----------------------------------------------------------------------------------------------------------------
Number of Responses per Total number Hours per Total burden
Instrument respondents respondent of responses response hours
----------------------------------------------------------------------------------------------------------------
Household Screening............. 168,674 1 168,674 0.083 14,000
Interview....................... 67,507 1 67,507 1.000 67,507
Screening Verification.......... 5,060 1 5,060 0.067 339
Interview Verification.......... 10,126 1 10,126 0.067 678
-------------------------------------------------------------------------------
Total....................... 168,674 .............. 251,367 .............. 82,524
----------------------------------------------------------------------------------------------------------------
Send comments to Carlos Graham, SAMHSA Reports Clearance Officer,
5600 Fisher Lane, Room 15E57A, Rockville, MD 20852 OR email him a copy
at [email protected]. Written comments should be received by
June 4, 2021.
Carlos Graham,
Social Science Analyst.
[FR Doc. 2021-06887 Filed 4-2-21; 8:45 am]
BILLING CODE 4162-20-P
